文献速递前列腺癌

跨性别与非二元患者的PSA检测与前列腺癌诊断率:单中心回顾性分析

Prostate Specific Antigen Testing and Prostate Cancer Diagnosis Rates Among Transgender and Non-Binary Patients: Retrospective Review of a Single-Institution Experience.
PubMed 文献 · Urology · 2025-07-31

本研究回顾性分析2019年3月至2021年2月单中心216例出生时指定男性且符合PSA筛查条件的跨性别/非二元患者,86例(39.8%)至少接受1次PSA检测,中位初始PSA为0.16 ng/mL,7例(8.1%)接受前列腺活检,4例(4.5%)诊断为前列腺癌。结论认为该人群PSA检测率低于已发表的顺性别男性数据,种族可能影响检测模式。

要点

  • 216例符合筛查条件的TGNB DMAB患者中仅39.8%接受过至少1次PSA检测。
  • 初始PSA中位值为0.16 ng/mL,接受性别肯定激素治疗或睾丸切除者间存在显著差异(P<.001)。
  • 4例(4.5%)诊断为前列腺癌,黑人/非裔美国人种族与PSA检测几率降低相关(OR 0.51,95%CI 0.25-1.01,P=.054)。

核心结论

  • TGNB DMAB人群PSA检测率低于已发表的顺性别男性数据,种族可能影响检测模式,需进一步研究验证。

研究设计与样本

  • 单中心回顾性研究,回顾2019年3月至2021年2月所有患者就诊记录,识别符合AUA指南PSA筛查条件的TGNB DMAB患者216例。

主要发现

  • 216例中86例(39.8%)在符合筛查年份内至少接受1次PSA检测。
  • 初始评估中位PSA为0.16 ng/mL(四分位距<0.04-1.14 ng/mL),接受性别肯定激素治疗或既往睾丸切除者间差异显著(P<.001)。
  • 检测队列中45例(52.3%)在初始评估后继续PSA检测或进一步检查,7例(8.1%)接受前列腺活检,4例(4.5%)诊断为前列腺癌。
  • 逻辑回归显示黑人/非裔美国人种族与接受任何PSA检测的几率降低相关(OR 0.51,95%CI 0.25-1.01,P=.054)。

关键数值与推荐

  • 符合AUA指南PSA筛查条件的TGNB DMAB患者纳入分析。
  • PSA检测率39.8%(86/216),活检率8.1%(7/86),前列腺癌诊断率4.5%(4/86)。
  • 初始PSA中位值0.16 ng/mL(IQR <0.04-1.14 ng/mL)。

临床怎么用

  • 应关注TGNB DMAB人群的PSA筛查,检测率偏低可能延误前列腺癌诊断。
  • 种族因素可能影响PSA检测决策,临床中需注意公平性。

局限性

  • 单中心回顾性设计,样本量有限,结果外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To characterize prostate-specific antigen (PSA) testing patterns, diagnosis, and treatment and management of prostate cancer in transgender and non-binary patients designated male at birth (TGNB DMAB) at a single tertiary care institution. METHODS: We retrospectively reviewed all patient encounters from March 2019 to February 2021 to identify TGNB DMAB eligible for PSA screening per American Urological Association guidelines. This cohort was analyzed to determine the rate of PSA testing, referral patterns, recommendations, and overall patterns of clinical care. RESULTS: Among 216 TGNB DMAB patients identified, 86 (39.8%) had at least 1 PSA during eligible screening years. Median PSA at initial evaluation was 0.16 ng/mL (interquartile range < 0.04-1.14 ng/mL), with significant differences between patients on gender-affirming hormonal therapy or prior orchiectomy (P <.001). In the testing cohort, 45 (52.3%) patients continued PSA testing or further workup after initial evaluation, and 7 (8.1%) patients underwent prostate biopsy. Four (4.5%) were diagnosed with prostate cancer. On logistic regression, Black/African-American race was associated with decreased odds of undergoing any PSA testing (odds ratio 0.51, 95% confidence interval 0.25-1.01, P = .054). CONCLUSION: The PSA testing rate among TGNB DMAB patients is low compared to published rates among cisgender men. Race may also influence PSA testing patterns in this population; however, further studies are required to validate our result.

来源:Urology,查看原文。版权归原作者所有。

引用

  1. Michael JA, Greenberg DR, Ascha M, et al. Prostate Specific Antigen Testing and Prostate Cancer Diagnosis Rates Among Transgender and Non-Binary Patients: Retrospective Review of a Single-Institution Experience. Urology. 2025. PMID: 40752851. doi:10.1016/j.urology.2025.07.055

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。